ITPR1抗体;ITPR1 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P11866(ITPR1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P11866(ITPR1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The ITPR1 antibody targets the inositol 1.4.5-trisphosphate receptor type 1 (ITPR1), a calcium channel protein primarily located on the endoplasmic reticulum (ER) membrane. ITPR1 plays a critical role in intracellular calcium signaling by mediating calcium release from the ER in response to inositol trisphosphate (IP3), a second messenger generated by phospholipase C activation. This calcium flux regulates diverse cellular processes, including neurotransmission, muscle contraction, apoptosis, and gene expression.

ITPR1 is widely expressed in tissues, with high levels in the brain, particularly in Purkinje cells of the cerebellum, and in secretory cells. Mutations or dysregulation of ITPR1 are linked to neurological disorders such as spinocerebellar ataxia types 15 and 29. Gillespie syndrome, and Huntington’s disease-like phenotypes. It has also been implicated in cancer and cardiovascular pathologies.

ITPR1 antibodies are essential tools in research for detecting protein expression, localization, and post-translational modifications. They are used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study ITPR1’s role in calcium signaling pathways and disease mechanisms. Commercial antibodies vary in specificity, often targeting epitopes in the N-terminal or C-terminal regions. Validation via knockout controls or siRNA is crucial due to potential cross-reactivity with other IP3 receptor subtypes (ITPR2/3). These antibodies advance understanding of ITPR1-related pathophysiology and therapeutic targeting.